Introduction
Acute myeloid leukemia (AML) is a kind of heterogeneous disease characterized by the clonal expansion of hematopoietic stem cells (HSCs) or hematopoietic progenitor cells (HPCs) in the bone marrow (BM), blood, and other tissues without differentiation.
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Yang et al DNMTs lead to the instability of genome structure and thus increase the possibility of cancer. 2 Since Ley et al 3 confirmed that DNMT3A mutations were highly recurrent in patients with de novo AML and associated with a poor outcome, many prognostic studies about DNMT3A-mutated AML have been carried out. [4] [5] [6] [7] [8] [9] [10] Occurring in ~20% of AML patients and having a high proportion of R882 mutation, 11, 12 DNMT3A mutations are often accompanied by FLT3-ITD, NPM1, IDH1, and IDH2 mutations. 13 NPM1 mutations were more common in patients with DNMT3A mutations than in DNMT3A wild-type patients. 14 mut/ FLT3-ITD positive ) was thought to be related with poor prognosis. 5 Hematopoietic stem cell transplantation (HSCT) has been shown to benefit the survival of all AML patients with DNMT3A mutations. 8, 9 Gale et al 15 argued that the presence of DNMT3A mutations should be considered as a poor-risk prognostic factor, irrespective of the NPM1 genotype as it may disturb the outcome. There have been few studies concerning DNMT3A mutations alone in AML patients together with studying the biological and clinical features with companion genes. Therefore, understanding the biological and clinical characteristics of these patients with DNMT3A mutations is important for estimating their event-free survival (EFS) and overall survival (OS) and likely advantageous in deciding the most suited clinical treatment.
Patients and methods Patients
We selected and enrolled 51 patients with diagnosed DNMT3A-mutated AML from The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov/). We collected data including age, gender, AML French-AmericanBritish classification subtypes, karyotype, cytogenetics' risk, white blood cell (WBC) count, BM blasts percentage, peripheral blood (PB) blasts percentage, relapse, mutated recurrent genes, and combined mutation genes, which were highly related to AML such as FLT3, IDH1/2, TET2, NRAS, CEBPA, PTPN11, KRAS, U2AF1, SMC1A, SMC3, and RAD21, with their clinical figures to include EFS and OS. Gene mutations were detected by NGS. Written informed consent was obtained from all patients. This study was approved by the Human Research Ethics Committee of Washington University.
Statistical analyses
The end points were EFS and OS. EFS is the time from the date of diagnosis to removal from the study due to the absence of complete remission, relapse, or death. OS is the time from the date of diagnosis to death due to any cause.
We compared different biological and clinical characteristics by using different statistical methods. The Student's t-test was applied to two group comparisons, and Chi-square test was used to compare the rate between them. Survival analysis was performed by Kaplan-Meier method. A twosided P-value of <0.05 was considered statistically significant. All statistical analyses were performed by the SPSS Version 20.0 software.
Results
Biological and clinical characteristics
In all of the 51 patients, NPM1 was the most frequently combined mutation gene (n=28, 54.9%), followed by FLT3 (n=21, 41.2%), IDH1 (n=11, 21.6%), and TET2 (n=6, 11.8%). The mutational spectrum of all genes with >5% mutation frequency is shown in Figure 1 . The biological and clinical characteristics are summarized in Table 1 .
Patients were divided into two groups depending on their NPM1 mutation states. There were 23 /L), BM blasts percentage (<70 vs ≥70%), PB blasts percentage (<70 vs ≥70%), mutated recurrent genes (<5 vs ≥5), genes with no <10 (19.6%) cases harboring FLT3-ITD/TKD and IDH1 changes (mutation vs wild type), and HSCT (yes vs no). The results are shown in Table 2 .
The NPM1 mutation had no influence on any of the abovementioned parameters in DNMT3A-mutated AML patients. EFS and OS between DNMT3A mut /NPM1 wild and DNMT3A mut /NPM1 mut groups showed no difference (P=0.504 and 0.586, respectively, Figure 2A and B). Furthermore, there was also no difference in EFS and OS between groups of patients with only chemical therapy (P=0.938 for EFS and P=0.942 for OS, Figure 2C and D) or HSCT treatment (P=0.940 for EFS and P=0.790 for OS, Figure 2E and F).
HSCT was an effective way for the treatment of DNMT3A-mutated AML patients (P=0.005 for EFS and P=0.001 for OS) in all of the 51 patients ( Figure 3A and B). We also compared the influence of different treatments in each group. The group of people with DNMT3A mut /NPM1 wild derived the best of HSCT treatment and had longer EFS and OS than patients who received only chemical therapy (P=0.043 for EFS and P=0.008 for OS, Figure 3C and D).
Patients in the other group with DNMT3A
mut /NPM1 mut did not show similar results (P=0.056 for EFS and P=0.053 for OS, Figure 3E and F).
For 
/NPM1
wild patients (n=4) and found that there were significant differences between these two groups (P2=0.004 for EFS in Figure 4A and P2=0.001 for OS in Figure 4B ), but there was no difference between the outcomes for the DNMT3A mut /FLT3 wild /NPM1 wild and DNMT3A mut /FLT3 mut /NPM1 mut groups (n=17, P1>0.1, Figure 4A and B).
Discussion
Our study showed that DNMT3A mutations in AML had higher BM blasts, higher FLT3-ITD/TKD mutation rate, and higher IDH2 mutation rate when combined with NPM1 mutation, but little difference in prognoses compared with NPM1 wild type. HSCT treatment benefited all patients who carried the DNMT3A mutation and was a better choice for the DNMT3A mut /NPM1 wild group. In Gale et al's 15 study, 80% of 272 patients with DNMT3A mutation concomitantly had the NPM1 mutation. We analyzed the biological and clinical features of 51 patients Figure 1 Mutational spectrum of all genes with >5% mutation frequency. Note: NPM1 was the most frequently combined mutation gene (n=28, 54.9%), followed by FLT3 (n=21, 41.2%), IDH1 (n=11, 21.6%), TET2 (n=6, 11.8%), SMC3 (n=6, 11.8%), IDH2 (n=5, 9.8%), NRAS (n=5, 9.8%), KRAS (n=4, 7.8%), MT-CYB (n=4, 7.8%), CEBPA (n=3, 5.9%), PTPN11 (n=3, 5.9%), U2AF1 (n=3, 5.9%), SMC1A (n=3, 5.9%), and RAD21 (n=3, 5.9%). with DNMT3A mutations and found NPM1 to be the most common accompanying mutation (n=28, 54.9%). This may be due to a relatively high percentage of patients older than 60 years in our study (47.1 vs 3%). Many genes participate in AML development. 16 Mutations in NPM1, IDH2, and biallelic CEBPA are favorable risk factors; 13 while FLT3-ITD positive, IDH1, TET2, 13 KRAS, 17 U2AF1, and PTPN11 are always associated with poor outcomes. 18, 19 Although showing different mutation rates in AML patients, genes such as NRAS, 20 SMC1A, SMC3, and RAD21 showed no influence in the prognosis. 21 Holmberg et al 22 did a basic clinical experiment on the relationship between DNMT3A and NPM1 and found that deficiency in DNMT3A enhanced the rearrangement of heterochromatin, which was triggered by the loss of NPM1. In our study, 35 15 We were not very consistent with their IDH2 mutation rates, and this may be related to the small number of cases.
Comparison of EFS and OS between different biological and clinical characteristics groups showed no difference. Similar to Xu et al's 23 conclusion, we also confirmed that HSCT is a better option for patients with DNMT3A mutations. We found that chemical therapy and HSCT treatment had the same effect in the DNMT3A mut /NPM1 mut group. We supposed that this may be due to high mutation rate of FLT3 in the NPM1-mutated group. Previous studies suggested that FLT3-ITD always results in significantly worse clinical outcomes and weakens the curative effect of conventional chemotherapy, 24 as well as shortening the EFS and OS in DNMT3A-mutated patients. 25 Only the R140 mutation in IDH2 seems to have prognostic meaning and is associated with a better outcome. 13 In our study, we found that IDH2 mutation only occurred in DNMT3A mut /NPM1 wild patients and three of the five IDH2 mutations happened at the R140 locus. This could be another reason why the DNMT3A mut / NPM1 mut group showed similar results to the DNMT3A mut / NPM1 wild group. There are some limitations to our study. First, the small sample size may have reduced the accuracy of our results. Second, our study has a retrospective design, the effectiveness of which is limited when compared to a prospective study.
Conclusion
All patients with the DNMT3A mutation benefited from HSCT, but those who also have NPM1 mutations should be treated carefully given their high FLT3-ITD/TKD rate, and hence, HSCT may not be better than chemotherapy for this group of patients. 
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